OTO1 Pemphigus vulgaris: An acquired blistering disease. (Otolaryngology-Head & Neck Surgery).OTO1 PEMPHIGUS VULGARIS pemphigus vul·gar·is n. Pemphigus occurring in middle age, in which cutaneous flaccid acantholytic suprabasal bullae and oral mucosal erosions are first localized but become generalized after a few months, forming blisters that break easily and are : AN ACQUIRED BLISTERING DISEASE. Kirby J. Scott, MC, USN, and Brian McKinnon, MD. University of Virginia Health Systems, Charlottesville. Pemphigus vulgaris is an autoimmune disorder Autoimmune disorder A disorder caused by a reaction of an individual's immune system against the organs or tissues of the body. Autoimmune processes can have different results: slow destruction of a particular type of cell or tissue, stimulation of an organ into , characterized by distinct clinical and histologic findings that prove vexing and formidable to the clinician. Caused by autoantibodies directed against the desmoglein adhesion molecules of squamous epithelial cells Squamous epithelial cells Thin, flat cells found in layers or sheets covering surfaces such as skin and the linings of blood vessels and esophagus. Mentioned in: Heartburn , pemphigus vulgaris has consistent immunopathologic characteristics that can be associated with an immune dysfunction. We report the case of a patient with pemphigus vulgaris localized to the oral cavity oral cavity n. The part of the mouth behind the teeth and gums that is bounded above by the hard and soft palates and below by the tongue and the mucous membrane connecting it with the inner part of the mandible. . This case presentation discusses the diagnosis of this autoimmune blistering disease and summarizes clinical, immunopathologic, and genetic advances involved in the induction of autoimmunity against desmoglein 3. Treatment with systemic immunosuppressive agents Immunosuppressive agents are a class of drugs which act to suppress the normal activity of the immune system. They are frequently used to prevent rejection of organs after organ transplant and also in the treatment of autoimmune disorders. as well as newer adjuvant therapies has reduced the pain, pruritis, and scarring in patients with these diseases. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion